Effect of lipid reduction on the progression of renal disease: A meta-analysis

Kidney International

Volumn 59, Issue 1, 2001, Pages 260-269

  Fried, Linda F ^a,b   Orchard, Trevor J ^a,b   Kasiske, Bertram L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Glomerular filtration rate; Hyperlipidemia; Nephropathy; Progressive renal disease; Proteinuria

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; LIPID PEROXIDATION; MEDICAL INFORMATION; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS;

EID: 0035166933     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00487.x     Document Type: Article

References (49)

1. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment
2. Lipoprotein metabolism and renal failure
3. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease
4. Renal injury of diet-induced hypercholesterolemia in rats
5. Renal changes in experimental hypercholesterolemia in normal and subdiabetic rabbits. II. Long-term studies
6. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
7. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rats 5/6 nephrectomy model of chronic renal failure
8. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
9. Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy
10. Predictors of microalbuminuria in individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study
11. Efecto de la pravastatina en la hipercolesterolemia asociada a proteinuria
12. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
13. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone
14. Can reduction in hypertriglyceridemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
15. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
16. Reduction in albuminuria predicts diminished progression in diabetic nephropathy
17. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study
18. Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus
19. Use of single voided urine samples to estimate quantitative proteinuria
20. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples
21. Selectivity of protein excretion in patients with nephrotic syndrome
22. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
23. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
24. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria
25. Effects of pravastatin on lipids levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients
26. Meta-analysis in clinical trials
27. Exploring heterogeneity in meta-analysis: Is L'Abbé plot useful?
28. Lipid-lowering therapy in patients with renal disease
29. Long-term effects of antihypertensive agents on proteinuria and renal function
30. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function
31. Can meta-analyses be trusted?
32. Meta-analysis in clinical research
33. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies
34. Towards a reduction in publication bias
35. Nephropathy of familial lecithin-cholesterol acyltransferase deficiency: Report of a case
36. Relationship between vascular disease and age-associated changes in the human kidney
37. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
38. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases
39. Effect of lipoproteins on cultured human mesangial cells
40. LDL stimulates mesangial fibronectin production and chemoattractant expression
41. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
42. Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
43. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
44. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin
45. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl
46. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia
47. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
48. Management of dyslipidemia in adults with diabetes